When should antinuclear antibody (ANA) testing be performed by indirect immunofluorescence assay (IFA), by enzyme‑linked immunosorbent assay (ELISA)/enzyme immunoassay (EIA), or by line immunoassay (LIA) ANA profile, and what are the practical advantages, limitations, and ideal testing sequence for each method?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Choosing the Right ANA Test: When to Order IFA, ELISA/EIA, or LIA/ANA Profile

IIFA on HEp-2 cells remains the reference standard for initial ANA screening and should be your first-line test when evaluating for systemic autoimmune diseases, as it provides the highest sensitivity (>95% in SLE) and critical pattern information that guides subsequent testing 1.

Testing Sequence Algorithm

First-Line Screening

  • Order ANA by IIFA (HEp-2 cells) for initial screening when clinical suspicion for systemic autoimmune disease exists
  • Screen at 1:160 dilution for adults (represents the 95th percentile in healthy controls) 1
  • IIFA detects the broadest range of autoantibodies including those not captured by solid-phase assays 1

When to Use Alternative Methods

ELISA/EIA as Initial Screen:

  • High-throughput laboratories requiring automation and rapid turnaround 1
  • Better sensitivity for specific diseases like SLE and systemic sclerosis (90-97% vs 80% for IFA in some studies) 2
  • Critical limitation: Lower specificity (36-94%) compared to IIFA (99%) 2
  • Must confirm positive ELISA results with IIFA to determine titer and pattern 2

LIA/ANA Profile:

  • Not for initial screening - use only after positive ANA screen 3
  • Best for identifying specific antigen subspecificities (Sm D, RNP 70kD, Ro52/Ro60) 3
  • Higher specificity than ELISA for anti-Sm (when Sm D detected), anti-RNP (when 70kD detected), and anti-SSA/Ro (when Ro60 detected) 3
  • Particularly useful when IIFA pattern suggests specific antibodies requiring confirmation

Practical Advantages and Limitations

IIFA (HEp-2 cells)

Advantages:

  • Detects antibodies to >100 different antigens 1
  • Pattern recognition guides reflex testing (homogeneous → anti-dsDNA; nucleolar → anti-Scl70, RNA polymerase; centromere → anti-CENP) 1
  • Highest specificity (99%) 2
  • Detects cytoplasmic patterns (anti-Jo-1, ribosomal P) missed by many solid-phase assays 1

Limitations:

  • Labor-intensive, requires highly trained technicians 1
  • Subjective interpretation variability 4
  • Up to 25% false positives in healthy populations at low dilutions 1
  • Time-consuming for high-volume laboratories 1

ELISA/EIA

Advantages:

  • Automated, objective, high-throughput 1
  • Quantitative results 5
  • Better sensitivity in low pre-test probability populations 6
  • Cost-effective for initial screening 2

Limitations:

  • Limited antigen panel (typically 6-12 antigens) 1
  • Cannot detect pattern information 1
  • Results should not be called "ANA test" or "ANA screen" - specify method used 1
  • Misses rare but clinically important antibodies 1

LIA/ANA Profile

Advantages:

  • Detects antigen subspecificities (Sm B/B' and D; RNP 70kD, A, C; Ro52 and Ro60) 3
  • Higher specificity than ELISA for certain antibodies 3
  • Good correlation for anti-CENP-B and anti-Jo-1 3

Limitations:

  • Lower sensitivity than ELISA for some antibodies (particularly anti-RNP) 3
  • Not suitable for initial screening 3
  • More expensive than standard ELISA 3

Ideal Testing Sequence

Standard Approach:

  1. IIFA at 1:160 → If positive, report titer and pattern
  2. Reflex to specific antibody testing based on pattern and clinical context 1
    • Homogeneous → anti-dsDNA, anti-histone
    • Speckled → anti-ENA panel (Sm, RNP, SSA/Ro, SSB/La, Scl-70)
    • Centromere → anti-CENP-B
    • Nucleolar → anti-Scl-70, RNA polymerase III

High-Volume Laboratory Alternative:

  1. ELISA/EIA screen → If positive
  2. Confirm with IIFA to determine titer and pattern 2
  3. LIA for antigen subspecificities if clinically indicated

Critical Pitfalls to Avoid

  • Never skip IIFA confirmation of positive solid-phase assays - you will miss pattern information essential for diagnosis 1
  • Do not refuse specific antibody testing (anti-Jo-1, ribosomal P, SSA/Ro) based on negative ANA screen in high clinical suspicion cases - these can be ANA-negative by IIFA 1
  • Always specify the method used on laboratory reports - clinicians often assume IIFA characteristics apply to all methods 1
  • Report each method's results separately when multiple platforms are used 1
  • In low pre-test probability populations, solid-phase assays may be more appropriate to reduce false positives 6

The 2014 international consensus emphasizes that IIFA remains the reference method while acknowledging that automated methods have a role in modern laboratories, provided their limitations are clearly communicated 1. The key is matching the test to your laboratory's capabilities and patient population while ensuring appropriate confirmatory testing.

Related Questions

When is it appropriate to order an antinuclear antibody IgG enzyme-linked immunosorbent assay (ANA IgG ELISA)?
What does an isolated positive antinuclear antibody (ANA) test indicate?
What is the significance of a high antinuclear antibody (ANA) result and how should it be evaluated?
When should an antinuclear antibody (ANA) test be ordered for a patient with intermittent systemic cold intolerance, unexplained anemia, and constitutional symptoms without a family history of autoimmune disease?
What is the antinuclear antibody (ANA) profile by immunoblot, its diagnostic accuracy, and what other methods are available for ANA detection?
What is the appropriate dosage and administration method for Debrox (carbamide peroxide 5% ear drops)?
What is the appropriate diagnostic evaluation and initial treatment for an adult patient presenting with unexplained recurrent fevers and systemic inflammation suggestive of an autoinflammatory disorder?
What SOAP note, including appropriate CPT code and ICD‑10 diagnosis, should be written for a 50‑year‑old female who presents with a one‑week history of severe throbbing oral pain, weight loss from inability to eat, large yellow‑white purulent lesions on the buccal mucosa, gums, lateral tongue and palate, and tongue swelling, and who requires a magic mouthwash and azithromycin (Z‑Pak) prescription?
Now that my serum sodium is normalized, can I resume citalopram (Celexa) at 40 mg orally as a home medication?
How does eating liver improve skin and hair health?
Should a patient with an extensive deep vein thrombosis (DVT) go to the emergency department (ED)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.